| Name | Title | Contact Details |
|---|---|---|
Alan Smith |
Chief Technology Officer | Profile |
ImmPACT-Bio is pioneering a novel strategy to surmount a major challenge compromising current Chimeric Antigen Receptor T-cell (CAR-T) therapy. Our technology addresses the need to differentiate cancerous from non-cancerous tissues impacting the safety of the treatment which is to date a major limitation in reaching effectiveness.
The mission of REVOLUTION Medicines is redesigning evolution`s products to treat serious diseases. The company discovers and develops new drugs by reconfiguring natural substances that are inherently rich with biological function as a result of natural selection. The company`s first drug candidates are innovative small molecules that exploit and improve upon the properties of amphotericin B, a powerful, broad-spectrum antifungal compound found in nature that has avoided generating significant drug resistance in 50 years of clinical use. Headquartered in Redwood City, Calif. at the intersection of Silicon Valley and the birthplace of biotechnology, REVOLUTION Medicines is a private company financed by top-tier investor Third Rock Ventures.
Tolerx is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bradmer Pharmaceuticals Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
XenoPort, Inc. is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.